Bulletin
Investor Alert

Market Pulse Archives

July 2, 2021, 12:12 p.m. EDT

Jazz's leukemia drug gets approved by the FDA

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Jazz Pharmaceuticals PLC (JAZZ)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Jazz Pharmaceuticals plc /zigman2/quotes/202658513/composite JAZZ +0.36% gained 3.5% in premarket trading on Thursday, the day after the Food and Drug Administration said it had approved the company's acute lymphocytic leukemia treatment Rylaze. The therapy is an orphan drug, meaning it affects less than 200,000 people in the U.S. The drug is expected to be available later this month; a spokesperson for the company said that's when the price will be made public. Jazz's stock is up 7.6% so far this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -0.08% is up 14.4%.

/zigman2/quotes/202658513/composite
US : U.S.: Nasdaq
$ 129.10
+0.46 +0.36%
Volume: 703,580
Sept. 21, 2021 4:00p
P/E Ratio
136.72
Dividend Yield
N/A
Market Cap
$7.89 billion
Rev. per Employee
$1.22M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,354.19
-3.54 -0.08%
Volume: 1.91B
Sept. 21, 2021 5:12p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.